FDA Approves Monjuvi plus Revlimid for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 11, p. 62
- Publication type:
- Article
Works matching IS 21644403 AND DT 2020 AND VI 10 AND IP 11
Results: 19
1
2
Blenrep Receives FDA Approval for Relapsed or Refractory Multiple Myeloma.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 11, p. 62
- Publication type:
- Article
3
Gavreto FDA Approved for Metastatic NSCLC with RET Fusions.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 11, p. 61
- Publication type:
- Article
4
Pembrolizumab New Standard of Care for Relapsed or Refractory Classical Hodgkin Lymphoma.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 11, p. 60
- By:
- Publication type:
- Article
5
Capmatinib Demonstrates Significant Antitumor Activity in Patients with Metastatic NSCLC Who Harbor MET Exon 14 Mutation.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 11, p. 59
- By:
- Publication type:
- Article
6
Interview with the Innovators.
- Published in:
- 2020
- Publication type:
- Interview
7
Select Ongoing Trials Currently Enrolling Patients with Lung Cancer.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 11, p. 52
- Publication type:
- Article
8
AACR's Cancer Disparities Progress Report Highlights Need for Healthcare Equity.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 11, p. 50
- By:
- Publication type:
- Article
9
Cabozantinib plus Nivolumab Offers New First-Line Treatment Option for Patients with Advanced Renal-Cell Carcinoma.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 11, p. 46
- By:
- Publication type:
- Article
10
Olaparib Significantly Improves Survival in Men with Metastatic Prostate Cancer and BRCA Mutations.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 11, p. 42
- By:
- Publication type:
- Article
11
"Practice-Changing" Results Seen with Adjuvant Abemaciclib plus Endocrine Therapy in HR-Positive, HER2-Negative Breast Cancer.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 11, p. 40
- By:
- Publication type:
- Article
12
The Impact of COVID-19 on the Oncology Care Model.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 11, p. 38
- By:
- Publication type:
- Article
13
Experts Agree That Innovation Is Key to Improving Value-Based Care.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 11, p. 36
- By:
- Publication type:
- Article
14
Strategies for Lowering the Cost of Cancer Care.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 11, p. 28
- By:
- Publication type:
- Article
15
Key Areas to Focus on Regarding the Medicare Proposed Rule 2021.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 11, p. 26
- By:
- Publication type:
- Article
16
Challenges for the Multiple Vaccine Candidates Targeting COVID-19.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 11, p. 18
- Publication type:
- Article
17
The Top 5 Killers of Team Culture That Leaders Need to Avoid.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 11, p. 1
- By:
- Publication type:
- Article
18
Impact of COVID-19 on Economic Trends in Oncology.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 11, p. 1
- Publication type:
- Article
19
Real-World Analysis Shows Survival Benefit with Adjuvant Immunotherapy in Melanoma.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 11, p. 1
- By:
- Publication type:
- Article